Rosacea is a chronic cutaneous inflammatory disease that affects mostly the facial skin, commonly more observed in caucasic population. Although, its pathophysiology is still not cleared it has been theorized to be caused by immunologic alterations and neurovascular dysregulation. Because of the complexity of rosacea, for a diagnosis, it can be categorized into four mainly clinical presentations: papulopustular, erythematotelangiectatic, ocular, and phymatous, but phenotypic presentations of rosacea are more heterogeneous leaving the diagnosis unclear, mistaken or even, and commonly can be confused with another type of disease. Currently, it is suggested, that there is a difference in temperature between the skin with rosacea and the normal skin, but this information is still not confirmed. Our aim is to establish an individual diagnosis criteria based in the difference of thermal patterns of healthy patients and patients with rosacea. This work was a single-blinded controlled study, where thirty healthy patients and twelve patients with rosacea underwent on application of four solutions with different lipid consistence and his temperature changes were monitored by digital infrared thermography. The results, depending on the solution applied, shows a statistically different temperature changes on the two kind of face surface, and so, we conclude that the digital infrared thermography could be used as an additional noninvasive medical diagnosis tool to rosacea detection. 489Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (liberty ad solo 1&2, chromos, cafe) Dupilumab (DUP), a fully human IL-4Ra mAb, inhibits signaling of IL-4 and IL-13, key drivers of type 2/Th2-mediated inflammation. DUP is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD). Our objective is to present efficacy and safety data from four phase 3 trials; pooled SOLO 1&2 (NCT02277743, NCT02277769 ) -DUP monotherapy vs placebo (PBO) in patients (pts) with moderate-to-severe AD; CHRONOS (NCT02260986) -DUP administered concomitantly with topical corticosteroids (DUP+TCS) vs PBO+TCS in pts with moderate-tosevere AD; and CAFÉ (NCT02755649) -DUP+TCS vs PBO+TCS in pts with severe AD not adequately controlled with, intolerant to, or medically inadvisable for oral cyclosporine A (CSA). Pts were randomized to PBO, DUP 300 mg every 2 wks (q2w), or DUP 300 mg qw for 16 wks in all trials. More DUP-treated pts vs PBO achieved an investigator's global assessment score 0/1 and 2-point improvement at Wk16 in all trials: pooled SOLO (37%/37% vs 9%; q2w/qw vs PBO), CHRONOS (43%/41% vs 12%), and CAFÉ (40%/39% vs 14%) (P<0.001 for all). Similar results were observed for % change in eczema area severity index and peak pruritus numerical rating scale scores respectively: pooled SOLO (-70%/-71% vs -34% and -47%/-49% vs -21%), CHRONOS (-81%/-82% vs -48% and -57%/-57% vs -31%), and CAFÉ (-80%/-78% vs -47% and -54%/-52% vs -25%) (P<0.001 for all). In all tria...